Research Use Only — Confirm to Continue

OptimalDosages.com publishes reference material for laboratory and educational use. Nothing here is medical advice, a prescription, or a recommendation for human administration.

By continuing you confirm you are 21 or older and that you are accessing this material in a research or educational capacity.

Research Use Only · Dosing data compiled from published literature · Not for human or veterinary use
OptimalDosages

Retatrutide / Cagrilintide Blend Dosage & Reconstitution

Retatrutide 5 mg + Cagrilintide 5 mg. Work out exactly what to draw for your own mix, see the doses used in research, and follow a week-by-week plan. Evidence tier: preclinical.

1Set Up Your Mix

10 mg/mL · 10000 mcg/mL
All answers assume a standard 1 mL U-100 syringe, where 1 unit = 0.01 mL. That is the usual insulin syringe and the one every number here is based on.

Your Answer — Retatrutide / Cagrilintide BlendYour Answer

—
24Draw To This Line
0.24That's This Many mL
4Doses In The Vial
0102030405060708090100 U-100 syringe · 1 mL · 100 units draw to 24
10 mg ÷ 1 mL = 10 mg/mL  →  2.4 mg ÷ 10 mg/mL = 0.24 mL  →  × 100 = 24 units—
Looks good. Draw to 24 units on a 1 mL syringe. That is an easy amount to measure, and this vial gives you 4 doses.

2Week-By-Week Plan — Retatrutide / Cagrilintide Blend

Start low, work up
WhenDoseHow OftenHow Many mLDraw ToNumber Of DosesPeptide Used
Low reported 1.2 mg once weekly (0.6 mg each) 0.12 mL 12 u 8 doses
Standard 2.4 mg once weekly (1.2 mg each) 0.24 mL 24 u 4 doses
Upper reported 4.8 mg once weekly (2.4 mg each) 0.48 mL 48 u 2 doses
Weeks until the top dose
8 weeks
Peptide used getting there
14.4 mg
Vials you'll need
2 × 10 mg
Once you're at the top dose
19.2 mg / 4 wk · 1.92 vials
Where this plan came from
Built from this peptide's dose range
Where this came from: Built from the doses listed for this peptide below — start at the lowest and step up, using the studies cited on this page. Nobody publishes a week-by-week plan for this peptide, so we built one: the doses are the researched ones shown below, and we simply put them in order from lowest to highest. Treat it as a starting point, not an official schedule.

3Common Doses — Retatrutide / Cagrilintide Blend

worked out for your mix
LevelDoseHow OftenHow Many mLDraw ToDoses In Vial
Weeks 1–4 1.2 mg once weekly 0.12 mL 12 u 4 4.8 mg
Weeks 5–8 2.4 mg once weekly 0.24 mL 24 u 4 9.6 mg
Week 9 onward
per 4 weeks from here on		 4.8 mg once weekly 0.48 mL 48 u 4 19.2 mg
Please read this. These numbers come from published research. They are here as reference, not as instructions. A lot of them come from lab studies rather than studies in people, and some of these peptides have never been given to a person at all.

About Retatrutide / Cagrilintide BlendAbout This Peptide

Multi-Compound Blends
Also known as
Retatrutide 5 mg + Cagrilintide 5 mg
Class
Multi-Compound Blends
Route
Subcutaneous
Half-life
Mixed (~6–8 days)
Evidence tier
Preclinical

Equal parts of a triple incretin agonist and an amylin analogue — 5 mg of each in a 10 mg vial, once weekly. The thing to understand before dosing it: the two components were trialled on very different scales. Retatrutide ran up to 12 mg weekly, cagrilintide only to 2.4 mg. Because a 1:1 blend moves both together, cagrilintide hits its ceiling at 4.8 mg total — and at that point retatrutide is still only at 2.4 mg, nowhere near its higher arms. Cagrilintide is what caps this blend, and pushing past it takes the amylin component beyond anything that has been tested.

Buy Retatrutide / Cagrilintide Blendthis peptide

Opens optimal-pep.com in a new tab

Where These Numbers Come From

Preclinical — Preclinical and in-vitro data only — no human dosing trials
See component entries: Retatrutide, Cagrilintide No blend-specific literature exists
Nothing has tested this pairing. The tiers above are capped by cagrilintide, whose 2.4 mg ceiling is reached well before retatrutide approaches its own upper arms.
Find on PubMed ↗
Cagrilintide plus semaglutide combination trials (CagriSema) Frías JP, et al. The Lancet, 2023
The closest tested analogue — an amylin analogue combined with an incretin agonist, though with semaglutide rather than retatrutide.
Find on PubMed ↗

Newest Studies — —

—
Not reviewed by us. This list is pulled straight from Europe PMC as papers are published. Nobody has checked whether these are any good, or whether they change anything above. The dose numbers on this page only ever change after a person reviews the evidence.

More peptides

Browse the full catalogue, or jump to a neighbouring compound.

NAD+ / MOTS-c / 5-Amino-1MQ Blend

A metabolic combination in a 120 mg vial, dosed daily and anchored to MOTS-c. MOTS-c is 8.3% of the contents, so a 1 mg daily MOTS…

BPC-157

A pentadecapeptide fragment derived from a sequence in human gastric juice. The published record is almost entirely preclinical re…

All 71 peptides

Every compound compared in one table: dose range, how often, half-life and evidence tier.